- Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data TranscriptFeb 08, 2024
- Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference TranscriptAug 16, 2023
- Adverum Biotechnologies Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Adverum Biotechnologies Inc ADVM-022 Update Call TranscriptJul 22, 2021
- Q4 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMar 01, 2021€107 (+7.00%)Earnings
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptNov 14, 2020
- Q2 2020 Adverum Biotechnologies Inc Earnings Call TranscriptAug 10, 2020€150 (-3.85%)Earnings
- Adverum Biotechnologies Inc Annual Shareholders Meeting TranscriptJun 23, 2020
- Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Q1 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMay 28, 2020€186 (+2.76%)Earnings
- Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call TranscriptMay 04, 2020
- Q4 2019 Adverum Biotechnologies Inc Earnings Call TranscriptMar 12, 2020€69 (-16.87%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptFeb 09, 2020
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Adverum Biotechnologies Inc Earnings Call TranscriptNov 07, 2019€72 (+2.13%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial TranscriptOct 12, 2019
- Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call TranscriptSep 12, 2019
- Q2 2019 Adverum Biotechnologies Inc Earnings Call TranscriptAug 08, 2019€107.02 (+2.47%)Earnings
Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call Transcript
Okay, good morning, everyone. I'm Leone Patterson, the Chief Executive Officer of Adverum. And thank you, everybody, for joining me today, who's in the room. We also have people via webcast.
And we've got 90 minutes of time here for this meeting, and I'll make my comments brief because you obviously want to get to our panel discussion and obviously the presentation. Just some housekeeping: You can find the presentation that we'll have today on our website. And then also further -- there will be some forward-looking statements today, and these are disclaimers associated with those.
So getting to the agenda for the day, I wanted to just welcome our 3 prominent retinal specialists who are in the front of the room here: Dr. Khanani, Dr. Boyer and Dr. Kiss. And today, we're going to go through a few areas of importance as it relates to ADVM-022. First of all, we'll have Dr. Kiss go through the preclinical data, but also he will cover the unmet need for wet AMD. And then we're going to have Dr. Boyer, who
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)